# Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea

> **NCT03508869** · NA · TERMINATED · sponsor: **Skin Laser & Surgery Specialists** · enrollment: 5 (actual)

## Conditions studied

- Erythema and Flushing Associated With Rosacea

## Interventions

- **DRUG:** Mirvaso® (brimonidine) topical gel, 0.33%
- **DRUG:** Dysport®
- **DRUG:** Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%

## Key facts

- **NCT ID:** NCT03508869
- **Lead sponsor:** Skin Laser & Surgery Specialists
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-27
- **Primary completion:** 2017-09-20
- **Final completion:** 2017-09-20
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** sponsor asked site to suspend study.
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03508869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03508869, "Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03508869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*